Navigation Links
Ferring Announces It Will Present Phase 3 Data for Cervical Ripening Agent at American College of Obstetricians and Gynecologists Annual Clinical Meeting
Date:5/2/2013

NEW ORLEANS, May 2, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present efficacy and safety data from its Phase 3 EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 61st annual clinical meeting of the American College of Obstetricians and Gynecologists in New Orleans, May 4 – 8, 2013.

Studies accepted for presentation include:

  • A poster presentation on Tues., May 7 (3:00 p.m. – 4:00 p.m. EDT), titled "Reduced Time to Delivery and Significantly Less Antibiotic Use" (lead author: Deborah A. Wing , M.D.; University of California, Irvine; Irvine, CA); and
  • A poster presentation on Tues., May 7 (3:00 p.m. – 4:00 p.m. EDT), titled "Misoprostol Vaginal Insert Reduces Time to Delivery in Nulliparous and Parous Women" (lead author: R. Lamar Parker , M.D.; Lyndhurst Clinical Research, Winston-Salem, NC).

*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of EXogenous Prostaglandin comparing the Efficacy and safety of the MVI 200 mcg to the Dinoprostone vaginal Insert for reducing Time to vaginal delivery in pregnant women at tErm.

For further information, contact:
Leila Boukassi
MSL New York
Leila.Boukassi@mslgroup.com; 646.500.7735

About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality biopharmaceutical company, active in global markets. The company identifies, develops and markets innovative products in the areas of general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopedics and urology. For more information, call 1-888-FERRING (1-
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
2. Ferring Pharmaceuticals Inc. Named 10th Fastest Growing New Jersey Company
3. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
4. Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
5. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
7. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
8. Misonix Announces New Distribution Agreement For Panama
9. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... BOTHELL, Wash. , Aug. 31, 2015 /PRNewswire/ ... ), the leading developer, manufacturer and marketer of ... storage and cryopreservation freeze media ... chain management app for smart shippers ... its customer TiGenix NV, an advanced biopharmaceutical company ...
(Date:8/29/2015)... y LONDRES, August 29, 2015 ... Inteligencia Anatómica para los sistemas de imagen ... reproducibles en Ecografía, tiempos de examen rápidos y un ... en mayor confianza diagnóstica en el proceso de detección ... PHG, AEX: PHIA) ha anunciado hoy el lanzamiento europeo ...
(Date:8/28/2015)... 2015 According to a new ... Lung, Prostate) Type (Protein & Genetic Biomarkers) Profiling Technology ... & Geography - Global Forecast to 2020", published by ... around 17,689.0 Million USD by 2020 at a CAGR ... 2020. Browse 191 Tables and 38 ...
Breaking Medicine Technology:BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5
... Rochester Medical Corporation (NASDAQ: ROCM ) will ... 5, 2011.  The Company will then hold a quarterly conference ... at 3:30 p.m. central time (4:30 p.m. eastern time). ... be accessed at Rochester Medical,s website at www.rocm.com . ...
... ("NeoStem" or the "Company") (NYSE Amex: NBS ), ... China, today announced that its majority owned Suzhou Erye Pharmaceutical ... Chempharm Brand Summit 2011 in China. During ... April 21st - 23rd, 2011, select recipients in the pharmaceutical ...
Cached Medicine Technology:Rochester Medical Announces Second Quarter 2011 Earnings Conference Call Thursday, May 5, 2011 2NeoStem's Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011 2NeoStem's Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011 3
(Date:8/31/2015)... ... August 31, 2015 , ... Kognito ... and assess their competencies in managing challenging conversations, announced today that Glenn Albright, ... Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) Summit ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Foundation for ... the facts about the role of heredity in below-the-belt gynecologic cancers. , ... Angelina Jolie Pitt’s decisions to have both her breasts and ovaries removed to ...
(Date:8/31/2015)... ... , ... “My mother and husband use oxygen therapy and the tubing irritates ... could be a comfortable way to prevent the irritation, so I invented this.” She ... more secure way to anchor the cannula tubing used in oxygen therapy and it ...
(Date:8/31/2015)... , ... August 31, 2015 , ... For 12 years, ... have acknowledged September 26th as Mesothelioma Awareness Day . On this day, and ... with several ways of becoming involved and helping the cause. , “One of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Westchester Insurance, ... Prairie, is teaming up with the Tarrant County chapter of Meals on Wheels ... Wheels is the oldest and largest national organization that supports the more than ...
Breaking Medicine News(10 mins):Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 3Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 4Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 2Health News:Westchester Insurance and the Meals on Wheels Association Announce Joint Charity Effort to Provide Nutritious Meals for Senior Citizens 3
... double by waiting even a day after discharge, study finds ... people who have stents implanted to keep an artery open ... Plavix immediately, and that ignorance nearly doubles their risk for ... study, which involved 7,402 people who had the thin tubes ...
... processed foods account for nearly 16% of daily intake, ... The added sugars in prepared and processed foods are ... cholesterol, raising levels of potentially dangerous triglcerides and possibly ... looked at a group of people representative of the ...
... D.C. Levels of epidermal growth factor receptor (EGFR) may ... prior to their breast cancer diagnosis, according to findings presented ... 2010, held here April 17-21. The goal of the ... of the Epidemiology Program at the Fred Hutchinson Cancer Research ...
... that when a thin person is seen laying down ... see an overweight person relaxing, it,s automatically assumed they,re ... of A,s Faculty of Physical Education and Recreation, says ... Berry says just because a person is overweight, it ...
... ... Administration (FDA) approved an Investigational New Drug (IND) for a clinical trial for ischemic ... ... April 20, 2010 -- Stemedica Cell Technologies, Inc. (Stemedica), a world leader ...
... computer games helped in any way , TUESDAY, April ... reports that popular brain-training computer games do not improve ... conducted by the Medical Research Council (MRC) in collaboration ... these brain games do little to boost the ability ...
Cached Medicine News:Health News:Many Don't Take Blood Thinner After Getting Stents 2Health News:Many Don't Take Blood Thinner After Getting Stents 3Health News:Added Sugars in Diet Threaten Heart Health 2Health News:Added Sugars in Diet Threaten Heart Health 3Health News:Increased EGFR levels may be an early marker of breast cancer 2Health News:FDA Approves Stemedica IND for Ischemic Stroke Clinical Trial 2Health News:'Brain Games' Do Not Make You Smarter 2Health News:'Brain Games' Do Not Make You Smarter 3